| Gene symbol | CEP290 | Synonyms | 3H11Ag, BBS14, CT87, JBTS5, LCA10, MKS4, NPHP6, POC3, SLSN6, rd16 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12q21.32 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | centrosomal protein 290 | ||||
| GTO ID | GTC2668 |
| Trial ID | NCT04855045 |
| Disease | Leber Congenital Amaurosis |
| Altered gene | CEP290 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | Sepofarsen|QR-110 |
| Phase | Phase2|Phase3 |
| Recruitment status | Recruiting |
| Title | An Open-Label, Dose Escalation and Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects <8 Years of Age With Leber Congenital Amaurosis Type 10 (LCA10) Due to the c.2991 +1655A>G (p.Cys998X) Mutation. |
| Year | 2021 |
| Country | Belgium|Brazil|Canada|Germany|Italy|Netherlands|United Kingdom |
| Company sponsor | ProQR Therapeutics |
| Other ID(s) | PQ-110-005 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||